人福医药(600079.SH)：二十碳五烯酸乙酯软胶囊获得药品注册证书

Core Viewpoint - The approval of the eicosapentaenoic acid ethyl ester soft capsule by the National Medical Products Administration marks a significant milestone for the company, enabling it to sell this product in the domestic market, which is expected to positively impact its business operations [1] Company Summary - The company's wholly-owned subsidiary, Wuhan Puke Pharmaceutical Co., Ltd., has received the drug registration certificate for eicosapentaenoic acid ethyl ester soft capsules [1] - This product approval enriches the company's product line, indicating a strategic expansion in its offerings [1] - The market launch of this product is anticipated to bring positive effects to the company's overall performance [1]